Compared efficiency of 3 strategies of therapeutic management of chronic hepatitis C. Influence on the occurrence of cirrhosis, 8 years after diagnosis;EFFICIENCE COMPAREE DE TROIS STRATEGIES DE PRISE EN CHARGE DE L'HEPATITE CHRONIQUE C. INFLUENCE SUR LE RISQUE DE CIRRHOSE A 8 ANS

Gastroenterologie Clinique et Biologique

Volumn 20, Issue 1, 1996, Pages 47-54

  Michel, Pierre ^a   Merle, Véronique ^a   Gourier, Claire ^a   Hochain, Patrick ^a   Colin, Raymond ^a   Czernichow, Pierre ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

Author keywords

alpha interferon; chronic viral hepatitis C; cirrhosis; decision analysis; efficiency; treatment

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

ARTICLE; CHRONIC HEPATITIS; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; COST BENEFIT ANALYSIS; ECONOMICS; PATHOLOGY; REVIEW; TIME;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; TIME FACTORS;

EID: 0030079403     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Micoud M. Rapport sur l'état de l'hépatite C en France. Ministère des Affaires Sociales et de l'Intégration : Paris, 1993.
2. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter H. Long-term clinical and histological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
3. Alter MJ, Margolis HS, Krawczynski K, Judson F, Mares A, Alexander J. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:899-905.
4. Weiland O, Schwarcz R. Hepatitis C: virology, epidemiology, clinical course, and treatment. Scand J Gastroenterol 1992;27:337-42.
5. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339:1543.
6. Pozzato G, Moretti M, Franzin F, Crocy L, Tiribelle C, Masayu T, et al. Severity of liver disease with different HCV clones. Lancet 1991;338:509.
7. Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy. N Engl J Med 1994;330:143.
8. Hoofnagle JH, Di Bisceglie AM, Shindo M. Antiviral therapy of hepatitis C. Present and future. J Hepatol 1993;17 (suppl. 3):130-6.
9. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987;316:250-8.
10. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz V, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
11. Gerber MA. Chronic hepatitis C: the beginning of the end of a time-honored nomenclature? Hepatology 1992;15:733-4.
12. Groupe MÉTAVIR. Quelle classification pour les hépatites chroniques? Les leçons du virus C. Gastroenterol Clin Biol 1994;18:403-6.
13. Hopf U, Möller B, Küther D, Stemerowicz R, Lobeck H, Lüdtke-Handjery A, et al. Long-term follow-up of post-transfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990;10:69-76.
14. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.
15. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of hepatitis C. Am J Gastroenterol 1993;88:240-3.
16. Seef LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-11.
17. Knodell RG, Conrad ME, Ishak KG. Development of chronic liver disease after acute non-A, non-B post-transfusion hepatitis: role of gammaglobulin prophylaxis in its prevention. Gastroenterology 1977;72:902-9.
18. Koretz RL, Stone O, Gitnick GL. The long-term course of non-A, non-B post-transfusion hepatitis. Gastroenterology 1980;79:893-8.
19. Altorfer J, Roten A, Pirovino M, Buhler H, Frosner G, Schmid M. Non-A, non-B viral hepatitis: occurrence, epidemiology and prognosis. Schweiz Med Wochenschr 1981;1: 982-4.
20. Alter MJ, Gerety RJ, Smallwood LA, Sampliner RE, Tabor E, Deinhardt F, et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982;145:886-93.
21. Realdi G, Alberti A, Rugge M, Rigoli AM, Tremolada F, Schivazappa L, et al. Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut 1982;23:270-5.
22. Shev S, Foberg U, Fryden A, Hermodsson S, Lindh G, Lindholm A, et al. Second generation hepatitis C ELISA antibody tests confirmed by the four antigens recombinant immunoblot assay correlate well with hepatitis viremia and chronic liver disease in Swedish blood donors. Vox Sang 1993;65:32-7.
23. Serfaty L, Nousbaum JB, Elghouzzi MH, Giral P, Legendre C, Poupon R. Prevalence, severity, and risk factors of liver disease in blood donors positive in a second-generation anti-hepatitis C virus screening test. Hepatology 1995;21:725-9.
24. Pateron D, Hartmann DJ, Duclos-Vallée JC, Jouanolle H, Beaugrand M. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol 1993;17:417-9.
25. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992;102:2155-62.
26. Mazzella G, Salzetta A, Casanova S, Morelli MC, Villanova N, Miniero R, et al. Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response. Dig Dis Sei 1994;39:866-70.
27. Jouet P, Roudot-Thoraval F, Dhumeaux D, Métreau JM, and the French Group for the study of NANB/C chronic hepatitis treatment. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994;106:686-90.
28. Poynard T, Bedossa P, Mathurin P, Naveau S, Delfraissy JF, Lemaigre G, et al. Efficacy of long term recombinant interferon alfa in patients with chronic hepatitis C. Gastroenterol Clin Biol 1991;15:615-9.
29. Saracco G, Rosina F, Torrani Cerenzia MR, Lattore V, Chiandussi L, Gallo V, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11(suppl):43-9
30. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Muray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
31. Davis G, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
32. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
33. Weiland O, Schwarcz R, Wejstal R, Norkrans G, Fryden A. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa 2b. Swedish experience. J Hepatol 1990;11 (suppl):57-62.
34. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13:393-7.
35. Douglas DD, Rakela J, Lin H, Blaine Hollander F, Taswell HF, Czaja AJ, et al. Randomized controlled trial of recombinant alfa-2a interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig Dis Sci 1993;38:601-7.
36. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994;21:1-3.
37. Camps J, Garcia-Granero M, Riezu-Boj J, Larrea E, De Alava E, Civeira P, et al. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol 1994;21:4-11.
38. Serfaty L, Giral P, Loria A, Andréani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994;21:12-3.
39. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj J, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993;34:1714-7.
40. Lin R, Schoeman M, Craig P, McDonald J, Batey RG, Farrell C. Randomized controlled trial of interferon α2b for chronic active hepatitis non-A, non-B: Biochemical and histological evidence of remission (abstract). Hepatology 1989;10:A310.
41. Realdi G, Diodati G, Bonetti P, Scaccabarozzi S, Alberti A, Ruol A. Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial. J Hepatol 1990;11 (suppl):68-71.
42. Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993;17(suppl. 3):123-6.
43. Capra F, Casaril M, Gabrielli GB, Tognella P, Rizzi A, Dolci L, et al. a interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers. J Hepatol 1993;18:112-8.
44. De Bac C, Grimaldi F, Clementi C, Duca F, Livolli D, Taliani G. Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C. Gut 1993;(suppl):135.
45. Ouzan D, Skaf R, Andréani T, Opolon P, Trépo C, Michel P, et al. Étude multicentrique de traitement par l'interferon α-2a de l'hépatite chronique C. Une dose d'attaque (6 MU) augmente-t-elle le taux de réponse à 6 et 12 mois? (résumé). Gastroenterol Clin Biol 1993;17:A42.
46. Picciotto A, Varagona G, Valle F, Covielle DA, Lapertosa G, Celle G. Interferon therapy in chronic hepatitis C. Evaluation of a low dose maintenance in responder patients. J Hepatol 1993;17:359-63.
47. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trépo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
48. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term followup of patients with chronic hepatitis C treated with α-interferon. Hepatology 1992;15:1013-6.
49. Romeo R, Pol S, Berthelot P, Brechot C. Eradication of hepatitis C virus RNA after alfa-interferon therapy. Ann Intern Med 1994;121:276-7.
50. Pawlotsky JM. Significance of indeterminate second generation RIBA and resolution by third generation RIBA. In: Hepatitis C virus new diagnosis tools. Paris: John Libbey Eurotext, 1994:17-28
51. e éd. Paris: 1994.
52. Observatoire National de l'Hépatite C : bilan initial (résumé). Gastroenterol Clin Biol 1995;19:81.
53. Serfaty L, Chazouillères O, Pawlotsky JM, Andréani T, Loria A, Poupon R. Niveau de virémie, atteinte hépatique et efficacité de l'interferon (IFN) chez les porteurs chroniques du virus de l'hépatite C (VHC) à transaminases normales (résumé). Gastroenterol Clin Biol 1995;19:85.
54. Nalpas B, Romeo R, Pol S, Thiers V, Carnot F, Berthelot P, et al. La détection de l'ARN-VHC dans le sérum des sujets anti-VHC positif à ALAT normales corrélé avec le statut VHC dans le foie et l'histologie (résumé). Gastroenterol Clin Biol 1995;19:84.
55. Hyrailles V, Larrey D, Blanc P, Gérolami V, Costes J, Dubois A, et al. Mise en évidence de l'existence de porteurs sains du virus de l'hépatite C (VHC). Association au génotype la (résumé). Gastroenterol Clin Biol 1995;19:90.
56. Alberti A, Morsíca G, Chemello L, Cavalletto D, Noventa F, Pontisso P, et al. Hepatitis C viremia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340: 697-8.
57. Booth JC, Foster OR, Galassini R, Goldin RD, Brown JL, Thomas HC. Chronic hepatitis C virus infections: predictive value of genotype and level of viremia on disease progression and response to interferon a. Gut 1995;36:427-32.
58. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995;122:161-8.
59. Chemello L, Diodati G, Bonetti P, Pontisso P, Alberti A, and the TVVH group. Treatment of chronic hepatitis C with different regimens of interferon alfa-2a (IFN-2a)(abstract). In: Proceedings of the International Symposium on Viral Hepatitis and Liver Disease. Tokyo: International Symposium on Viral Hepatitis and Liver Disease, 1993:233.
60. Lino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon a 2b. A multicenter study. Dig Dis Sci 1992;38:612-8.
61. Reichard O, Glaumann H, Fryden A, Norkrans G, Schwarcz R, Sönnerborg A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995;21:918-22.